029 Group SE

Earnings Release • Aug 26, 2003

News Details

Ad-hoc | 26 August 2003 09:36

Rhein Biotech N.V. english

Rhein Biotech N.V. reports 2003 Half Year results Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Maastricht, 26 August 2003 Rhein Biotech N.V. reports for the first Half Year 2003 net sales of 14.2 million Euro. The EBITDA was 2.2 million Euro, while the income from operations (EBIT) was – 2.1 million Euro. Rhein Biotech’s net income for the first half of 2003 was -4.6 million Euro. The company’s cash position at the end of June 2003 was 30.0 million Euro. The numbers are not comparable with the same period of last year due to: – the discontinuation of the trade goods – change from US GAAP to Dutch GAAP – certain amounts in the current statement have been reclassiefied to conform with the Berna Biotech group standards – negative currency impact on the Korean Wong versus EURO – an additional provision for a doubtfull debt had a negative impact on the result The trend of prices in the Hepatitis B sales franchise is better than the trend of quantities. Rhein expects a positive development in the quantities for the second Half Year 2003. end of ad-hoc-announcement (c)DGAP 26.08.2003 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: Rhein Biotech is a member of the Berna Biotech Group, a leading player for innovation in vaccines. For further information: Rhein Biotech N.V. Company Contact: Béatrice Keller Communications Manager investor.relations@bernabiotech.com ——————————————————————————– WKN: 919544; ISIN: NL0000230324; Index: Listed: Geregelter Markt in Frankfurt (General Standard); Freiverkehr in Düsseldorf, Hamburg, Hannover, München und Stuttgart 260936 Aug 03